文献速递外周动脉疾病慢性静脉疾病

股静脉作为经皮股腘动脉旁路通道术后1年静脉结局

Venous outcomes at 1 year after using the femoral vein as a conduit for passage of percutaneous femoropopliteal bypass.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-01-08

DETOUR 1研究为前瞻性单臂国际试验,纳入78例患者(82处股腘动脉病变),评估股静脉作为经皮股腘动脉旁路(DETOUR)通道的安全性。术后1年仅2.4%患者出现同侧症状性深静脉血栓,无肺栓塞,静脉管腔面积多数保留,部分患者静脉直径代偿性增加。

要点

  • DETOUR术后1年症状性深静脉血栓发生率低(2.4%),无肺栓塞。
  • 多数患者(86.8%)股静脉管腔面积保留≥55%。
  • 部分患者静脉直径代偿性增加,基线静脉直径较小者更易出现。

核心结论

  • 经静脉途径的DETOUR旁路术后深静脉血栓和阻塞性并发症发生率低。
  • 股静脉横截面积得以保留,部分患者静脉直径随时间代偿性增加。
  • 结果支持下肢深静脉系统作为DETOUR经皮股腘动脉旁路通道的可行性和安全性。

研究设计与样本

  • 前瞻性、单臂、国际多中心试验(DETOUR 1),共8个中心参与。
  • 纳入78例患者(82处股腘动脉病变),基线股静脉通畅且直径≥10 mm。
  • DETOUR操作:经对侧股总动脉入路,置入TORUS覆膜支架,经股静脉进入并在膝上腘动脉重新进入动脉,支架重叠部署为动脉-动脉通道。

主要发现

  • 20.7%病例存在重复股静脉。
  • 86.8%患者股静脉管腔面积保留≥55%。
  • 静脉直径代偿性增加的患者基线平均静脉直径小于无代偿增加者(P = .0414)。
  • 随访至1年,仅2例(2.4%)发生同侧症状性深静脉血栓,无肺栓塞。

临床怎么用

  • 对于复杂股腘动脉外周动脉疾病,经静脉旁路可作为开放手术旁路的经皮替代方案。
  • 术后需关注静脉血栓事件,但本研究中症状性深静脉血栓和肺栓塞发生率低。
  • 静脉管腔面积多数保留,部分患者静脉直径可代偿性增加,支持该通道的可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The DETOUR 1 study was performed to assess the safety of the femoral vein as a "pass through" conduit for covered stent placement during fully percutaneous femoropopliteal bypass, also known as the DETOUR procedure. METHODS: At eight participating centers in this prospective, single-arm, international trial, 78 patients (82 femoropopliteal lesions) were enrolled. All patients had patent femoral veins measuring ≥10 mm in diameter at baseline. The DETOUR procedure involved delivery of a series of TORUS stent grafts, deployed from contralateral common femoral artery access, to the ipsilateral proximal superficial femoral artery, with entry into the femoral vein and re-entry into the arterial vasculature at the above-the-knee popliteal artery. The TORUS stent grafts are deployed in an overlapping configuration as an arterial-arterial conduit. Due to this novel transvenous approach, we assessed specific considerations related to the venous system to analyze the risk of risk of venous thromboembolic complications. Symptomatic deep vein thrombosis, nonocclusive material associated with the graft such as benign endovenous graft-associated material, pulmonary embolism, Venous Clinical Severity Score (VCSS) and Villalta scores, and luminal occupancy by the stent graft were assessed as the ratio of cross-sectional areas of the stent graft to the native vein at baseline and 1 year after the procedure. RESULTS: A duplicate femoral vein was present in 20.7% of cases. The majority of patients (86.8%) had a femoral vein luminal area preservation of ≥55%. Thirty-two patients experienced an increase in the vein diameter over time after the procedure, but this pattern of venous remodeling was not uniform. The patients who had a compensatory increase in the vein diameter had a smaller average baseline vein diameter compared with the patients who did not have a compensatory increase in vein diameter (P = .0414). Only two patients (2.4%) developed ipsilateral symptomatic deep vein thrombosis) through 1 year of follow-up. There were no pulmonary embolism in any patient in the series. The overall VCSS and Villata scores did not change during follow-up. Mean VCSS and Villata were 0.8 ± 1.4 and 0.5 ± 1.1 at 1 year, compared with 0.6 ± 1.0 and 0.4 ± 0.9 at baseline, respectively. CONCLUSIONS: As a percutaneous alternative to open surgical bypass for complex femoropopliteal peripheral arterial disease, the transvenous bypass has a low rate of deep venous thrombotic and obstructive complications. Cross-sectional vein area is preserved, and in some patients, the compensatory vein diameter increases with time, supporting the feasibility and safety of using the lower extremity deep venous system as a pass-through conduit for the DETOUR percutaneous femoropopliteal bypass. TRIAL REGISTRATION: NCT02471638.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Schneider PA, Krievins DK, Halena G, et al. Venous outcomes at 1 year after using the femoral vein as a conduit for passage of percutaneous femoropopliteal bypass. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33429092. doi:10.1016/j.jvsv.2020.12.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。